Literature DB >> 28787087

Bone health and SATB2-associated syndrome.

Y A Zarate1, M Steinraths2, A Matthews2,3, W E Smith4, A Sun5, L C Wilson6, C Brain7, J Allgove7, B Jacobs8, J L Fish9, C M Powell10,11, W W Wasserman2,3, C D van Karnebeek3,12,13, E L Wakeling14, N S Ma15.   

Abstract

SATB2-associated syndrome (SAS) is a rare disorder caused by alterations in the special AT-rich sequence-binding protein 2 (SATB2). Skeletal abnormalities such as tibial bowing, osteomalacia, osteopenia or osteoporosis have been reported suggesting a higher frequency of skeletal complications in SAS. The optimal timing, necessity, and methodology for routine assessment of bone health in individuals with SAS, however, remain unclear. We report molecular and phenotypic features of 7 individuals with SAS documented to have low bone mineral density (BMD) ascertained by dual-energy X-ray absorptiometry (DXA), often preceded by tibial bowing. The lowest BMD Z-scores ranged -2.3 to -5.6. In 4 individuals, total alkaline phosphatase levels were elevated (2 with elevated bone fraction) around the time of low BMD documentation. A clinically significant fracture history and a diagnosis of pediatric osteoporosis were present in 4 individuals. Pamidronate treatment in 2 children improved BMD. In conclusion, low BMD, fractures, and tibial bowing are relatively common skeletal complications in individuals with SAS. DXA is a useful tool when evaluating a child with SAS suspected to have low BMD and the results might alter clinical management.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990SATB2; Pamidronate; bone density; osteopenia

Mesh:

Substances:

Year:  2017        PMID: 28787087     DOI: 10.1111/cge.13121

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  5 in total

1.  Satb2 regulates proliferation and nuclear integrity of pre-osteoblasts.

Authors:  Todd Dowrey; Evelyn E Schwager; Julieann Duong; Fjodor Merkuri; Yuri A Zarate; Jennifer L Fish
Journal:  Bone       Date:  2019-07-17       Impact factor: 4.398

2.  Individuals with SATB2-associated syndrome with and without autism have a recognizable metabolic profile and distinctive cellular energy metabolism alterations.

Authors:  Yuri A Zarate; Jenny-Li Örsell; Katherine Bosanko; Sujata Srikanth; Lauren Cascio; Rini Pauly; Luigi Boccuto
Journal:  Metab Brain Dis       Date:  2021-03-04       Impact factor: 3.584

3.  A novel mutation of SATB2 inhibits odontogenesis of human dental pulp stem cells through Wnt/β-catenin signaling pathway.

Authors:  Tianyi Xin; Qian Li; Rushui Bai; Ting Zhang; Yanheng Zhou; Yuehua Zhang; Bing Han; Ruili Yang
Journal:  Stem Cell Res Ther       Date:  2021-12-04       Impact factor: 6.832

4.  SATB2-associated syndrome: characterization of skeletal features and of bone fragility in a prospective cohort of 19 patients.

Authors:  M Mouillé; M Rio; S Breton; M L Piketty; A Afenjar; J Amiel; Y Capri; A Goldenberg; C Francannet; C Michot; C Mignot; L Perrin; C Quelin; J Van Gils; G Barcia; V Pingault; G Maruani; E Koumakis; V Cormier-Daire
Journal:  Orphanet J Rare Dis       Date:  2022-03-03       Impact factor: 4.123

5.  Silencing of miR-483-5p alleviates postmenopausal osteoporosis by targeting SATB2 and PI3K/AKT pathway.

Authors:  Fujiang Zhao; Yier Xu; Yulong Ouyang; Zhexu Wen; Guihao Zheng; Ting Wan; Guicai Sun
Journal:  Aging (Albany NY)       Date:  2021-02-17       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.